Proceedings from a CME symposium held during the 61st
ASH Annual Meeting. Featuring perspectives from Drs Mark Levis,
Daniel A Pollyea, Richard M Stone and Andrew H Wei.
Introduction
Program Overview: Dr Neil Love (00:00)
Evolving Paradigms in Up-Front Treatment for Older
Patients or Those Ineligible for Intensive
Chemotherapy
Case (Dr Pollyea): A woman in her mid-30s with
acute myeloid leukemia (AML) who is unable to undergo intensive
induction chemotherapy because of refusal to accept blood products
on religious grounds achieves a complete response to
venetoclax/azacytidine (11:28)
Case (Dr Pollyea): A women in her late 60s
with AML who is ineligible for intensive induction chemotherapy
receives venetoclax/azacitidine as first-line therapy (15:18)
Faculty Presentation: Dr Pollyea (19:39)
Assessment, Incidence and Clinical Significance of FLT3
Mutations in AML
Case (Dr Stone): A man in his mid-40s with AML
with a FLT3-ITD mutation receives 7 + 3 induction in combination
with midostaurin and undergoes allogeneic transplant (47:53)
Case (Dr Stone): A man in his early 60s who
underwent allogenic transplant 1.5 years ago for high-risk
myelodysplastic syndrome (MDS) presents with AML with a FLT3-ITD
mutation and receives gilteritinib (50:46)
Faculty Presentation: Dr Stone (52:31)
Long-Term Treatment for Patients with AML with IDH
Mutations
Case (Dr Levis): A woman in her mid-80s who
previously received azacitidine and lenalidomide for MDS presents
with AML with an IDH1 mutation and receives ivosidenib
(1:13:52)
Case (Dr Levis): A man in his early 60s who is
receiving enasidenib for AML with an IDH2 mutation develops
differentiation syndrome causing acute kidney injury (1:19:11)
Faculty Presentation: Dr Levis (1:21:56)
Other Novel Agents and Promising Strategies Under
Evaluation for Patients with AML
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.